![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Therapy for hepatitis B virus (HBV) infection, the most common worldwide cause of viremia and chronic liver disease, is currently limited to interferon preparations and nucleoside or nucleotide analogs. Although these treatments result in suppression of HBV replication, virologic rebounds are common when treatment is ended or when viral resistance emerges. This review considers novel approaches targeting viral or host factors involved in the HBV lifecycle, as well as immunomodulatory strategies that are likely to be used concomitantly with antiviral drugs in future research.